Sign In

Drug-induced Liver Injury Due to Chemotherapeutic Agents

Date/Time 

  • Friday, October 20, 2-6 pm

Program Chair  

  • Paul H. Hayashi, MD, MPH 

Continuing Education Information

CME –  3.5 AMA PRA Category 1 Credits™ 

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify chemotherapeutic agents, both old and new, that can cause liver injury.
  • Improve competency in DILI recognition and diagnosis.
  • Discuss the challenges in chemotherapeutic drug development and regulation.

Session Description/Needs Statement

A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.

Session I

  • 2-2:05 pm
    Welcome and Introduction
    Paul H. Hayashi, MD, MPH
  • 2:05-3:45 pm
    Session I
  • 2:05-2:25 pm
    LiverTox and the Challenge of the Growing Number of New Chemotherapeutic Agents 
    Jay H. Hoofnagle, MD, FAASLD
  • 2:25-2:45 pm
    Incidence and Differential Diagnosis of Abnormal Liver Biochemistries in Oncology Patients: Challenges for Diagnosing DILI
    Robert J. Fontana, MD, FAASLD
  • 2:45-3:05 pm
    DILI from Cytotoxic Chemotherapy (Includes Tyrosine Kinase Inhibitors)
    K. Rajender Reddy, MD, FAASLD
  • 3:05-3:25 pm
    Sinusoidal Obstructive Syndrome
    Laurie D. DeLeve, MD, PhD, FAASLD
  • 3:25-3:45 pm
    DILI From Biologic and Antibody Conjugates
    Wen Jin Wu, MD, PhD
  • 3:45-3:55 pm
    Panel Discussion
  • 3:55-4:25 pm
    Break

Session II

  • 4:20-4:40 pm
    HBV Reactivation in Oncology Patients
    Adrian M. Di Bisceglie, MD, FAASLD
  • 4:40-5 pm
    Mitigating and Monitoring DILI Risk in Cancer Drug Development and Clinical Trials
    Arie Regev, MD
  • 5-5:20 pm
    Mitigating and Monitoring Liver Toxicity from Immune Checkpoint Inhibition
    Lorraine Pelosof, MD, PhD
  • 5:20-5:35 pm
    Panel Discussion / Q&A
  • 5:35-5:55 pm
    Controversial Issues / Clinical Cases
    Paul B. Watkins, MD, FAASLD
  • 5:55-6 pm
    Wrap-Up
    Paul H. Hayashi, MD, MPH